Foghorn Therapeutics Inc. announced on October 10, 2024, that the first patient has been dosed with FHD-909 (LY4050784) in a Phase 1 trial. This trial targets SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) identified as the primary patient population for the study. FHD-909 is a first-in-class oral, highly potent compound that demonstrates high selectivity for SMARCA2 (BRM) over SMARCA4.
The Phase 1 open-label, multicenter trial will assess the safety, tolerability, and initial efficacy of FHD-909 in patients with locally advanced or metastatic solid tumors harboring a SMARCA4 alteration. Preclinical studies have indicated that FHD-909 is a potent and selective SMARCA2 inhibitor, showing robust anti-tumor monotherapy activity and favorable tolerability in vivo.
This program is part of a U.S. 50/50 co-development and co-commercialization collaboration with Eli Lilly, which leads the clinical development of the Phase 1 trial. The dosing of the first patient represents an important milestone for both Foghorn and its partnership with Lilly, advancing a promising synthetic lethality strategy for prevalent SMARCA4 mutations.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.